Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 24, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 23, 2026 — +33.1% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$875.00 – $900.00Entry zone — fair-value band

$890.84Published — price the day we called it

$1,006.64Target — the price the thesis aimed for

$1,249.45Peak — highest point inside the window, not a realized return

$1,185.87Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 19 days.

At window close

+33.1%

realized, from the publication price to the last close inside the window

Peak gain

+40.3%

peak, from the publication price — not a realized return

S&P 500, same window

+3.7%

SPY over the identical days, dividend-adjusted

Window close

$1,185.87

last close inside the window, ended July 23, 2026

Peak price

$1,249.45

peak on July 7, 2026 — not a realized return

Days to target

The thesis — published April 24, 2026

Predicted growth

+13%

over the measurement window

Target price

$1,006.64

the price the thesis aimed for

Entry zone

$875.00 – $900.00

the fair-value band we waited for

Price at publication

$890.84

published April 24, 2026

Confidence

77%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly looks well positioned for the next quarter because its business is still growing while the stock has cooled from earlier strength. New LillyDirect updates help the sales and distribution picture, and the recent price dip gives a clearer base for a rebound. Healthcare leaders like Lilly often hold up when markets get shaky.

Primary drivers

Strong drug franchises continue to drive sales and profits
LillyDirect news improves how products reach customers
The pullback gives a more orderly timing for recovery
Healthcare leaders can be steadier during market stress

How it played out

LLY: target reached in 19 days

Lyra published a 13% growth thesis from $890.84, with a target of $1,006.64. The thesis pointed to continued sales and profit growth from strong drug franchises, LillyDirect updates that could improve product distribution, a recent pullback that offered a base for recovery, and the relative steadiness of healthcare leaders during market stress.

The stock reached the target in 19 days. It later peaked at $1,249.45 on July 7, a 40.3% gain within the window, and ended at $1,185.87. The published thesis played out and exceeded its stated target.

What happened during the window

On April 30, Lilly reported first-quarter results and raised its full-year guidance. On May 6, the company announced an additional $4.5 billion investment across two Indiana manufacturing sites.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals